TUESDAY 7 MAY
17:00 - 18:00
TABLE 1: Clinical Utility of ctDNA as Predictive IO Marker
Moderator: Helen Rizos,
PhD, Head, Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Australia
- Impact of
tumour load, location
and activity on ctDNA levels
- Sensitivity of ctDNA
- New technologies for ctDNA analysis
TABLE 2: Toward Leveraging Publicly Accessible Clinical Trials Data- Sharing, Dissemination, and Repurposing
Moderator: Sanchita Bhattacharya,
PhD, Bioinformatics Project Scientist, Bakar Computational Health Sciences Institute, University of California San Francisco, United States
- Data sharing in clinical and translational science- Risk and Benefits
- Data Standards for clinical trials data sharing
- Data Reproducibility, reuse
and repurposing- Challenges and Opportunities
TABLE 3: Multiplex Immunofluorescence in Clinical Practice
Moderator: Nicolas A. Giraldo-Castillo, MD,
PhD, Pathology Resident, Johns Hopkins University School of Medicine, United States
- What are the major challenges we are facing to standardize large-scale mIF stains in paraffin-embedded tissue?
- How can we best optimize the stain and analysis of
- How far are we from using mIF in daily clinical practice?
TABLE 4: Application of MALDI-TOF MS and Nucleic-Acid Amplification to Microbiological and Virological Diagnosis
Moderator: Adriana Calderaro, MD,
PhD, Associate Professor, Clinical Microbiology, Unit of Microbiology and Virology, Department of Medicine and Surgery, University Hospital of Parma, Italy
- Identification of viruses
- Identification of bacteria and fungi
- Identification of parasite
TABLE 5: Point-of-Care vs. Central Lab Testing
Moderator: Oliver Liesenfeld, MD, CMO,
Inflammatix, United States
point of impact, satellite and central lab
- What are the clinical requirements/medical needs?
- What are the assay/instrument requirements?
- What about data flow, integration into electronic medical records?
- Who performs the testing?
- Who is in charge of quality control?
TABLE 6: How to Survive the in vitro Diagnostic Regulation (Regulation (EU) 2017/746)
Moderator: Michael Messenger,
PhD, Head of Personalised Medicine and Health, Leeds Centre for Personalised Medicine and Health, University of Leeds, United Kingdom
- What is IVDR and how does it differ from the current directive?
- What are the implications of IVDR on healthcare systems and commercial test developers?
- What is the community doing to prepare?
TABLE 7: Technological Advances for cfDNA and Other Circulating Biomarkers: Challenges and Strategies
Moderator: Jörg Tost,
PhD, Director Laboratory for Epigenetics & Environment, Laboratory for Epigenetics & Environment, Centre National de Recherche en Génomique Humaine (CNRGH), CEA – Institut de Biologie Francois Jacob, France
- What will be the technological platforms for the next generation of circulating biomarker assays?
- What are
key challenges for current assays?
- Which biomarker to choose for nucleic acid analysis: circulating molecules vs. exosomes?
TABLE 8: Has ctDNA Won Over CTCs in the Clinical Space?
Moderator: Lorena Diéguez,
PhD, Group Leader, Department of Life Sciences, Nano4Health Unit, Medical Devices Research Group, International Iberian Nanotechnology Laboratory, Portugal
- What information can still be provided by CTCs that is not accessible by any other circulating biomarker in oncology?
- What challenges do we face to implement functional studies on CTCs?
- How can this information be applied in the clinic?
WEDNESDAY 8 MAY
18:05 - 19:05
TABLE 1: Open Innovation in Action
Moderator: Pierre Meulien,
PhD, Executive Director, Innovative Medicines Initiative, Belgium
- Extension of open innovation concept to general R&D ecosystem
- Examples of successes of this principle
- How open innovation can accelerate implementation of research outcomes in health systems
TABLE 2: Potential of cfDNA as a Point-of-Care Marker in Emergency and Critical Care Settings
Moderator: Andrea Regner, MD,
PhD, Professor, Cellular and Molecular Biology Applied to Health, Course of Medicine, Lutheran University of Brazil, Canoas, Brazil
- Prognosis prediction in acute brain injuries;
- Defining cutoff of cfDNA that favors high specificity for brain death outcome;
- Clinical utility of cfDNA quantification in acute medical care scenarios.
TABLE 3: Extracellular Vesicles (EVs) as Biomarkers and Mediators of Oncologic Disease
Moderator: Bruno Costa-Silva, PhD, Systems Oncology, Group Leader, Champalimaud Foundation, Portugal
- Isolation and characterization of EVs
- Tumour- and Host-derived EVs
- EVs heterogeneity
- Emerging technologies for EVs studies
TABLE 4: Circulating Tumor Cells as Liquid Biopsy in Cancer Patients
Moderators: Catherine Alix-Panabieres, PhD, Assistant Professor; Director, Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, France
Klaus Pantel, MD, Professor, Chairman, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
- Technology for CTC detection
- Biology of CTCs
- In vitro and in vivo expansion of CTCs: establishment of CTC lines
- Clinical Relevance of CTCs